To deepen the understanding of the clinicopathological features and prognosis of patients with HER2-low breast cancer, we retrospectively analyzed the data of our hospital from January 2012 to September 2021, comparing the differences between HER2-low and HER2-zero patients. This evidence concerns the gene ERBB2 and breast cancer.